Get started
Author

Liezl Heyman

Observed name: L. Heyman
ORCID: 0000-0002-2518-215X
Observed ORCID: 0000-0002-2518-215X
OpenAlex ID: A5000185857
High Mobility Group Box 1 in Human Cancer
2020 · Bernardo L. Rapoport, Helen C. Steel, et al. · Cells · 72
Tumor-Infiltrating Lymphocytes (TILs) in Early Breast Cancer Patients: High CD3+, CD8+, and Immunoscore Are Associated with a Pathological Complete Response
2022 · Bernardo Leon Rapoport, Simon Nayler, et al. · Cancers · 34
PDF
Systemic Immune Dysregulation in Early Breast Cancer Is Associated With Decreased Plasma Levels of Both Soluble Co-Inhibitory and Co-Stimulatory Immune Checkpoint Molecules
2022 · Bernardo L. Rapoport, Helen C. Steel, et al. · Frontiers in Immunology · 22
Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3
2023 · Bernardo L. Rapoport, Helen C. Steel, et al. · Frontiers in Oncology · 21
A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative
2023 · Bernardo Leon Rapoport, Marcial Garcia-Morillo, et al. · Supportive Care in Cancer · 17
37P Dysregulation of soluble immune checkpoint proteins in newly diagnosed early breast cancer patients
2020 · B.L. Rapoport, H. Steel, et al. · Annals of Oncology · 4
Pathological complete response in early stage HER-2 positive breast cancer patients, receiving neoadjuvant chemotherapy/ Trastuzumab, in a single breast unit in Johannesburg
2021 · A. Bellomo, C. Benn, et al. · The Breast · 2
PDF
Her-2 positive and TNBC patients receiving neoadjuvant chemotherapy are associated with a high pathological complete response rate – results from real-world outcomes in a multidisciplinary setting
2021 · B.L. Rapoport, T. Smit, et al. · The Breast · 2
PDF
Dysregulation of immune checkpoint proteins in patients with newly diagnosed early breast cancer undergoing neoadjuvant chemotherapy: A comparison between patients with triple negative breast cancer (TNBC) and non-TNBC.
2023 · Teresa Smit, Bernardo Leon Rapoport, et al. · Journal of Clinical Oncology · 1
97 Effect of administration of neoadjuvant chemotherapy to newly diagnosed early breast cancer patients on the depressed plasma levels of soluble co-stimulatory and co-inhibitory immune checkpoint molecules
2022 · Bernardo Rapoport, Helen Steel, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Dysregulation of soluble immune checkpoint proteins in newly-diagnosed early breast cancer patients.
2021 · Bernardo Leon Rapoport, Helen C Steel, et al. · Journal of Clinical Oncology · 1
ICES (International Carboplatin Emesis Survey) for the evaluation of the emetogenicity of continuous cycles of carboplatin-based chemotherapy with focus on nausea: A MASCC emesis study group, prospective, observational, real-world multi-centric study.
2021 · Bernardo Leon Rapoport, Alexandre Chan, et al. · Journal of Clinical Oncology · 1
Immune-phenotyping of peripheral blood mononuclear cells from patients with early triple-negative breast cancer: Identification of a systemic immunosuppressive CD3+ CD4+ CD39+ Treg subset.
2024 · Bernardo Leon Rapoport, Nicole Chicken, et al. · Journal of Clinical Oncology
PDF
490P Metastatic breast cancer is associated with increased levels of soluble forms of TIM-3 and LAG-3 and decreased levels of soluble forms of GITR, GITR-L, CD27, CD28, CD40, CD86, ICOS, PD-L1, CTLA-4 and BTLA
2023 · T. Smit, B.L. Rapoport, et al. · Annals of Oncology
261P Dysregulation of immune checkpoint proteins in newly- diagnosed early breast cancer patients undergoing neoadjuvant chemotherapy: A comparison between TNBC and non-TNBC patients
2023 · B.L. Rapoport, H. Steel, et al. · Annals of Oncology
PDF
96 Metastatic breast cancer is associated with increased levels of soluble inhibitory immune checkpoint proteins and decreased levels of soluble stimulatory immune checkpoint proteins
2022 · Bernardo Rapoport, Helen Steel, et al. · Journal for ImmunoTherapy of Cancer
PDF
Dysregulation of immune checkpoint proteins in patients with newly diagnosed early breast cancer.
2022 · Bernardo Leon Rapoport, Helen C. Steel, et al. · Journal of Clinical Oncology
Abstract P4-04-11: Dysregulation of immune checkpoint proteins in newly- diagnosed early breast cancer patients
2022 · Bernardo Leon Rapoport, Helen C Steel, et al. · Cancer Research
Treatment outcomes in triple negative breast cancer patients undergoing neoadjuvant chemotherapy.
2022 · Bernardo Leon Rapoport, Liezl Heyman, et al. · European Journal of Surgical Oncology
150P Dysregulation of immune checkpoint proteins in newly-diagnosed early breast cancer patients
2021 · B.L. Rapoport, H. Steel, et al. · Annals of Oncology
PDF
Abstract PS6-31: Correlations between tumor-infiltrating lymphocytes, CD3, CD8 cells, and Immunoscore®, with pathological CR and time to progression in triple-negative breast cancer patients undergoing neoadjuvant chemotherapy
2021 · Bernardo Leon Rapoport, Jérôme Galon, et al. · Cancer Research
Abstract PS3-12: Prediction of pathological complete response to neoadjuvant chemotherapy in early triple negative breast cancer patients by serial breast ultrasound examination
2021 · Bernardo Rapoport, Teresa Smit, et al. · Cancer Research
Abstract PS17-36: Dysregulation of soluble immune checkpoint proteins in newly - diagnosed early breast cancer patients
2021 · Bernardo Rapoport, Helen Steel, et al. · Cancer Research
743 High levels of stromal tumor infiltrating lymphocytes, CD3, CD8 cells & Immunoscore® are associated with pathological CR and time to progression in TNBC patients undergoing neo-adjuvant chemotherapy
2020 · Bernardo Rapoport, Jérôme Galon, et al. · Journal for ImmunoTherapy of Cancer
754 Dysregulation of soluble immune checkpoint proteins in newly – diagnosed early breast cancer patients
2020 · Bernardo Rapoport, Helen Steel, et al. · Journal for ImmunoTherapy of Cancer
Works count: 31
Citation count: 178
H-index: 5
I10-index: 5
Year
Topic
Type